Document is current

Article History

Received: 22 December 2023

Accepted: 16 April 2024

First Online: 2 July 2024

Competing interests

: No shareholdings in pharmaceutical companies. No shareholdings in companies developing psychedelics. J.R. and N.L.M. provide services for the psychoactive trials group at King’s College London. The psychoactive trials group at King’s College London receives grant funding (received and managed by King’s College London) from Compass Pathways, Supporting Wounded Veterans, Multidisciplinary Association for Psychedelic Studies, Beckley PsyTech and National Institute for Health Research. J.R. is supported by the U.K. National Institute for Health Research (NIHR) via Clinician Scientist Fellowship Awards to J.R. (CS-2017-17-007) and by the NIHR Biomedical Research Centre at South London, Maudsley National Health Service Foundation Trust, and King’s College London. J.R. has attended trial-related meetings paid for by Compass Pathways, Ltd. He has consulted for Beckley PsyTech and Clerkenwell Health; and he is employed by Sapphire Medical Clinics, a private medical clinic. A.C. has received honoraria for presentations and/or serving on advisory boards from the following pharmaceutical companies: Janssen, Lundbeck, Allergan, and Livanova. N.L.M. has received consulting fees (PAST) from Compass Pathways PLC, Small Pharma Ltd and Beckley Psytech Ltd. R.K. provides services for the clinical trials at the Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University. The DES receives grant funding from Compass Pathways and Beckley PsyTech.